📰 ReutersReutersCodex · 实盘不做把握 3/10
北京时间·🕒 发布 08-03 20:25:11时区推断·⟳ 抓取 08-03 20:25:19·⚡ 决策 08-04 06:41:06 +10h15m·84.5 天前
Latigo和BlossomHill启动美国IPO拟分别募资2.88亿美元和1.328亿美元
Latigo拟以16至18美元发行1600万股、募资2.88亿美元并寻求10.8亿美元估值，BlossomHill拟募资1.328亿美元并寻求约4.94亿美元估值。
📄 原文Reuters↗ 原文
Drug developers Latigo Biotherapeutics and BlossomHill Therapeutics launched their U.S. initial public offerings on Mon…
不做 Latigo Biotherapeutics（LTGO.US）
仅为IPO启动，尚无已上市二级市场行情和可执行入场价，当前不做。
不做 BlossomHill Therapeutics（BLSM.US）
仅为IPO启动，尚无已上市二级市场行情和可执行入场价，当前不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 medium · price-in 风险 medium ↗
关键理由
- Latigo拟以16至18美元发行1600万股、募资2.88亿美元并寻求10.8亿美元估值，BlossomHill拟募资1.328亿美元并寻求约4.94亿美元估值。
主要风险
- 两家公司只是启动IPO，股票尚未上市交易，当前没有可回测的二级市场入场价。
工具调用 · 历史记录,结果未知(3 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,650 字
Drug developers Latigo Biotherapeutics and BlossomHill Therapeutics launched their U.S. initial public offerings on Monday riding the wave of biotech listings.
Biotech IPOs are tapping renewed capital flows, but the rally could stall if continuing Middle East tensions fuel inflation, keep interest rates higher for longer and raise funding costs for cash-hungry drug developers.
Here are some more details:
Thousand Oaks, California-based Latigo Biotherapeutics is targeting a $1.08 billion valuation and aims to raise $288 million by offering 16 million shares priced between $16 and $18 each.
It is focused on developing non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
Its lead product candidate, LTG-001, is an oral inhibitor currently in development as a potential treatment for moderate to severe acute pain, including postoperative pain.
Goldman Sachs, Jefferies, Leerink Partners and Guggenheim Securities are the underwriters for the offering. Latigo intends to list its shares on Nasdaq under the symbol “LTGO”.
San Diego, California based BlossomHill Therapeutics is targeting a $494.38 million valuation and aims to raise $132.8 million by offering 7.8 million shares priced between $15 and $17 each.
Founded in 2020, it is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.
J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital and H.C. Wainwright & Co. are the underwriters for the offering. BlossomHill intends to list its shares on Nasdaq under the symbol “BLSM."
Biotech IPOs are tapping renewed capital flows, but the rally could stall if continuing Middle East tensions fuel inflation, keep interest rates higher for longer and raise funding costs for cash-hungry drug developers.
Here are some more details:
Thousand Oaks, California-based Latigo Biotherapeutics is targeting a $1.08 billion valuation and aims to raise $288 million by offering 16 million shares priced between $16 and $18 each.
It is focused on developing non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.
Its lead product candidate, LTG-001, is an oral inhibitor currently in development as a potential treatment for moderate to severe acute pain, including postoperative pain.
Goldman Sachs, Jefferies, Leerink Partners and Guggenheim Securities are the underwriters for the offering. Latigo intends to list its shares on Nasdaq under the symbol “LTGO”.
San Diego, California based BlossomHill Therapeutics is targeting a $494.38 million valuation and aims to raise $132.8 million by offering 7.8 million shares priced between $15 and $17 each.
Founded in 2020, it is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.
J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital and H.C. Wainwright & Co. are the underwriters for the offering. BlossomHill intends to list its shares on Nasdaq under the symbol “BLSM."
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。